Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
AZAstraZeneca PLC logo

AstraZeneca PLC (AZN)

New York Stock Exchange · Currency in USD
$171.49 ▼ -1.08 (-0.63%)
At close: Oct 23, 4:00 PM ET. Market closed.
$171.49 ▲ +0.00 (+0.00%)
After hours: Oct 23, 5:27 PM ET

Summary

Previous Close
$172.57
Open
$171.28
Day's Range
$169.51 – $171.75
52 Week Range
$153.41 – $212.71
Volume
3,666,259
Avg. Volume
3,172,739
Market Cap
$265.96B
Beta (5Y Monthly)
0.21
PE Ratio (TTM)
25.56
EPS (TTM)
$6.73
Earnings Date
Oct 30, 2026
Forward Dividend & Yield
$2.12 (1.24%)
Ex-Dividend Date
Aug 7, 2026
1y Target Est
$186.67

Profile: AstraZeneca PLC

Sector
Healthcare
Industry
Drug Manufacturers - General
Full-time employees
96,100
CEO
Pascal Claude Roland Soriot

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris.

Earnings

Next report: Fri, Oct 30, 2026
EPS estimate $2.60 · Revenue est. $16.01B
DateEst.Actual
Jul 27, 2026$2.50$2.63Beat
Apr 29, 2026$2.57$2.58Beat
Feb 10, 2026$2.09$2.12Beat
Nov 6, 2025$2.28$2.38Beat
Jul 29, 2025$2.18$2.18Beat
Apr 29, 2025$2.20$2.48Beat

Analyst view

Consensus price target
$186.67 ▲ +8.9%
Range $158.00 – $216.00
Rating: Buy
Buy 49% · Hold 37% · Sell 15%

Get free alerts on AZN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.